Infections in patients with systemic lupus erythematosus (SLE) receiving intravenous cyclophosphamide. Systemic Lupus Erythematosus Cyclophosphamide Infections
Conditions
Interventions
Patients with systemic lupus erythematosus who received IV cyclophosphamide in Chonburi Hospital
Health Services Research
SLE patients who received IVCY
Sponsors
Principal Investigator
Eligibility
Sex/Gender
All
Age
15 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients diagnosed with systemic lupus erythematosus (SLE) according to the 1997 ACR criteria and/or the 2012 SLICC classification criteria. 2.Patients who received intravenous cyclophosphamide from medical departments at Chonburi Hospital, either as inpatients or outpatients. 3.Patients who developed any infection within 12 weeks after receiving intravenous cyclophosphamide.
Exclusion criteria
Exclusion criteria: 1.Incomplete essential data in the medical records.2.Patients lost to follow-up after receiving intravenous cyclophosphamide for more than 12 weeks. 3.SLE patients who received intravenous cyclophosphamide for other conditions, such as malignancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Infection occurrence Within 12 weeks after each IVCY administration Medical record documentation of clinical or microbiological diagnosis of infection within 12 weeks post-IVCY | — |
Secondary
| Measure | Time frame |
|---|---|
| Factors associated with severe infection At baseline and within 12 weeks post-IVCY Demographic and clinical characteristics | — |
Countries
Thailand
Contacts
Public ContactWimol Jangsombatsiri
Chonburi Hospital
Outcome results
None listed